

Jingwei Li

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7965272/publications.pdf>

Version: 2024-02-01

37
papers

761
citations

623734

14
h-index

552781

26
g-index

39
all docs

39
docs citations

39
times ranked

970
citing authors

#	ARTICLE	IF	CITATIONS
1	Mediators of the Effects of Canagliflozin on Heart Failure in Patients With Type 2 Diabetes. <i>JACC: Heart Failure</i> , 2020, 8, 57-66.	4.1	93
2	Early Change in Albuminuria with Canagliflozin Predicts Kidney and Cardiovascular Outcomes: A Post Hoc Analysis from the CREDENCE Trial. <i>Journal of the American Society of Nephrology: JASN</i> , 2020, 31, 2925-2936.	6.1	82
3	Mediators of the effects of canagliflozin on kidney protection in patients with type 2 diabetes. <i>Kidney International</i> , 2020, 98, 769-777.	5.2	69
4	Effects of Canagliflozin on Amino-Terminal Pro-B-Type Natriuretic Peptide. <i>Journal of the American College of Cardiology</i> , 2020, 76, 2076-2085.	2.8	50
5	Prognostic Value of Secreted Frizzled-Related Protein 5 in Heart Failure Patients With and Without Type 2 Diabetes Mellitus. <i>Circulation: Heart Failure</i> , 2020, 13, e007054.	3.9	46
6	Effects of the SGLT2 inhibitor canagliflozin on plasma biomarkers TNFR-1, TNFR-2 and KIM-1 in the CANVAS trial. <i>Diabetologia</i> , 2021, 64, 2147-2158.	6.3	45
7	Poly(Lactide-Co-Glycolide)-Monomethoxy-Poly-(Polyethylene Glycol) Nanoparticles Loaded with Melatonin Protect Adipose-Derived Stem Cells Transplanted in Infarcted Heart Tissue. <i>Stem Cells</i> , 2018, 36, 540-550.	3.2	44
8	The effects of canagliflozin on gout in type 2 diabetes: a post-hoc analysis of the CANVAS Program. <i>Lancet Rheumatology</i> , 2019, 1, e220-e228.	3.9	38
9	Serum Diamine Oxidase as a Hemorrhagic Shock Biomarker in a Rabbit Model. <i>PLoS ONE</i> , 2014, 9, e102285.	2.5	34
10	Effects of canagliflozin on cardiovascular, renal, and safety outcomes in participants with type 2 diabetes and chronic kidney disease according to history of heart failure: Results from the CREDENCE trial. <i>American Heart Journal</i> , 2021, 233, 141-148.	2.7	30
11	Canagliflozin and Kidney-Related Adverse Events in Type 2 Diabetes and CKD: Findings From the Randomized CREDENCE Trial. <i>American Journal of Kidney Diseases</i> , 2022, 79, 244-256.e1.	1.9	23
12	Self-reported Snoring Patterns Predict Stroke Events in High-Risk Patients With OSA. <i>Chest</i> , 2020, 158, 2146-2154.	0.8	21
13	Sleep duration and risk of cardiovascular events: The SAVE study. <i>International Journal of Stroke</i> , 2020, 15, 858-865.	5.9	19
14	Association Between Circulating GDF-15 and Cardio-Renal Outcomes and Effect of Canagliflozin: Results From the CANVAS Trial. <i>Journal of the American Heart Association</i> , 2021, 10, e021661.	3.7	16
15	Low-dose versus standard-dose alteplase in acute ischemic stroke in Asian stroke registries: an individual patient data pooling study. <i>International Journal of Stroke</i> , 2019, 14, 670-677.	5.9	15
16	Expression and anatomical distribution of TIM-containing molecules in Langerhans cell sarcoma. <i>Journal of Molecular Histology</i> , 2013, 44, 213-220.	2.2	14
17	Galuteolin attenuates cerebral ischemia/reperfusion injury in rats via anti-apoptotic, anti-oxidant, and anti-inflammatory mechanisms. <i>Neuropsychiatric Disease and Treatment</i> , 2019, Volume 15, 2671-2680.	2.2	14
18	Upregulated ATF6 contributes to chronic intermittent hypoxia-afforded protection against myocardial ischemia/reperfusion injury. <i>International Journal of Molecular Medicine</i> , 2016, 37, 1199-1208.	4.0	13

#	ARTICLE	IF	CITATIONS
19	Effects of canagliflozin on myocardial infarction: a <i>post hoc</i> analysis of the CANVAS programme and CREDENCE trial. <i>Cardiovascular Research</i> , 2022, 118, 1103-1114.	3.8	13
20	Sodium-glucose cotransporter-2 inhibition and ocular outcomes in patients with type 2 diabetes: A systematic review and meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 252-257.	4.4	12
21	Mechanisms of action of the sodium-glucose cotransporter-2 (SGLT2) inhibitor canagliflozin on tubular inflammation and damage: A <i>post hoc</i> analysis of the CANVAS trial. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 1950-1956.	4.4	11
22	Validation of the simplified modified Rankin scale for stroke trials: Experience from the ENCHANTED alteplase-dose arm. <i>International Journal of Stroke</i> , 2021, 16, 222-228.	5.9	9
23	Sex differences in blood pressure after stroke. <i>Journal of Hypertension</i> , 2019, 37, 1991-1999.	0.5	6
24	An exploration of the heterogeneity in effects of SGLT2 inhibition on cardiovascular and all-cause mortality in the EMPA-REG OUTCOME, CANVAS Program, DECLARE-TIMI 58, and CREDENCE trials. <i>International Journal of Cardiology</i> , 2021, 324, 165-172.	1.7	6
25	Reasons for hospitalizations in patients with type 2 diabetes in the CANVAS programme: A secondary analysis. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 2707-2715.	4.4	6
26	Sex Differences in Disease Profiles, Management, and Outcomes Among People with Atrial Fibrillation After Ischemic Stroke: Aggregated and Individual Participant Data Meta-Analyses. <i>Women S Health Reports</i> , 2020, 1, 190-202.	0.8	5
27	Worse prognosis in women, compared with men, after thrombolysis: An individual patient data pooling study of Asian acute stroke registries. <i>International Journal of Stroke</i> , 2021, 16, 784-791.	5.9	5
28	Canagliflozin, serum magnesium and cardiovascular outcomes—Analysis from the CANVAS Program. <i>Endocrinology, Diabetes and Metabolism</i> , 2021, 4, e00247.	2.4	5
29	Ethnicity and Other Determinants of Quality of Functional Outcome in Acute Ischemic Stroke. <i>Stroke</i> , 2020, 51, 588-593.	2.0	4
30	The function of RNase L and its degradation mechanism in cardiac acute ischemic injury. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2020, 25, 400-411.	4.9	4
31	27-OR: Effect of Canagliflozin on Total Hospitalization for Heart Failure Events in Patients with Type 2 Diabetes and Chronic Kidney Disease. <i>Diabetes</i> , 2020, 69, .	0.6	2
32	1216-P: The Effects of Canagliflozin on Uric Acid and Gout in Patients with Type 2 Diabetes in the CANVAS Program. <i>Diabetes</i> , 2019, 68, .	0.6	1
33	Reply. <i>JACC: Heart Failure</i> , 2020, 8, 427.	4.1	0
34	Canagliflozin Reduces All-cause Hospitalization in Patients with Type 2 Diabetes Mellitus. <i>Metabolism: Clinical and Experimental</i> , 2021, 116, 154509.	3.4	0
35	1098-P: Biomarkers of Tubular Injury and Effects of Canagliflozin in the CANVAS Trial. <i>Diabetes</i> , 2020, 69, .	0.6	0
36	1130-P: Mediators of the Effects of Canagliflozin (CANA) on Heart Failure (HF) and CV Death in Patients with Type 2 Diabetes (T2D) and Chronic Kidney Disease (CKD). <i>Diabetes</i> , 2020, 69, .	0.6	0

#	ARTICLE	IF	CITATIONS
37	1120-P: Association between the Inflammatory Marker GDF-15 and Kidney Disease Progression: Results from the CANVAS Trial. <i>Diabetes</i> , 2020, 69, .	0.6	0